Inclusion Criteria:

- Histological or cytological confirmation of prostate adenocarcinoma

- Advanced prostate carcinoma.

- Previous treatment with hormones

- Levels of testosterone < 50 ng/dL

- Good hematological, liver and kidney function

- Previous treatment with surgery or radiotherapy, at least 4 weeks since end of
treatment is allowed (the patient should have been recovered from any side effects.

Exclusion Criteria:

- Previous chemotherapy (estramustine included).

- Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)

- Previous treatment with radiotherapy (isotopes) or previous radiotherapy over > 25%
of the marrow

- Any malignant process with a free disease interval under 5 years, exception done to
non-melanoma skin cancer.

- Concomitant serious diseases

- Concomitant treatment with any other neoplassic therapy (exception done to LHRH
agonists and/or biphosphonates).

- Contraindication for the treatment with estramustine.

- Previous history of pulmonary embolism, thromboembolic disease, previous treatment
with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.

- Previous history of pulmonary spillage or ascitis.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.